-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。CMIの第1四半期決算は、売上高が3%増の84億ドルとなったものの、EBITDAマージンは17.9%から15.4%に低下し、発電事業とトラック製造事業の業績の乖離を反映し、まちまちの結果となりました。発電事業は引き続き好調で、パワーシステム事業は売上高が19%増の20億ドル、EBITDAマージンが29.5%に拡大しました。一方、配電事業は売上高が7%増の31億ドルとなり、マージンも改善しました。これは、データセンターにおけるバックアップ電源システムの需要がかつてないほど高まったことが要因です。対照的に、トラック関連事業は逆風に直面し、エンジン事業の売上高は4%減の27億ドル、マージンも10.4%に低下し、コンポーネント事業は5%減の25億ドルとなりました。経営陣は通期業績見通しを引き上げ、売上高成長率を8~11%(従来予想の3~8%)、EBITDAマージンを17.75~18.50%(従来予想の17.0~18.0%)と予測した。北米のオンハイウェイ市場は底打ちからの回復の兆しを見せており、発電需要の勢いも継続していることから、年初にもかかわらず業績見通しの引き上げを後押ししている。
Related Articles
American Electric Power CEO Says Speed to Market Key Issue in Load Connection
American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%
MGE Energy Q1 Earnings, Revenue Rise
MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%
Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.